Recently, KeYe Biotech was awarded the title of "High Growth Enterprise" in the 2024 "Julong Leading Talent" (Category D) evaluation by the Pingshan District Science and Technology Innovation Committee of Shenzhen. This recognition highlights the company’s outstanding innovation capacity. With this approval, the company will enjoy greater autonomy and leverage government incentives and subsidies to attract top talent, further driving the high-quality development of the biopharmaceutical industry in Pingshan District.
Innovation-Driven Growth
KeYe Biotech places technological innovation at the core of its development strategy. In recent years, the company has continuously increased its R&D investment, establishing a comprehensive research and development system and an efficient innovation platform. A unique pharmacological analysis and drug development platform has been created, focusing on RNA helicase activity analysis and drug screening, laying a solid foundation for the company's future market competitiveness.
Product Portfolio Optimization
KeYe Biotech has developed innovative anti-tumor drugs with independent intellectual property rights. KY1, the company’s flagship product, has received clinical trial approvals in both China and the United States and has officially entered Phase I clinical trials. At the same time, the company is actively planning for the future by accelerating the development of new products. In addition to anti-tumor drugs, an original equipment IVD (in vitro diagnostic) reagent kit project was introduced this year. Over the next few years, a series of innovative drugs are expected to be launched, offering patients more treatment options.